Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.56 |
| ▸ | RARG | P13631 | 15/20 | 0.56 |
| ▸ | RARA | P10276 | 15/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898555 | 1.00 | RARB (0.56) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL3900887 | 1.00 | RARB (0.56) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL3898558 | 1.00 | RARB (0.56) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL13938671 | 1.00 | RARB (0.56) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL15869879 | 0.94 | RARB (0.46) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL14047270 | 0.90 | RARB (0.53) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL4510443 | 0.88 | RARB (0.60) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL4510438 | 0.88 | RARB (0.60) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL3907997 | 0.87 | RARB (0.49) | RARBRARGRARARXRANR2E1 | |
| SCHEMBL3894316 | 0.87 | RARB (0.49) | RARBRARGRARARXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701934-B1 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7432388-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432388-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | TSANG KWOK Y | 2008-04-24 | — | — | US | disclosed |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | TSANG KWOK Y | 2008-04-24 | — | — | US | disclosed |
| US-7253319-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253319-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | RARB, RARG, RARA | RARB 1/4885RARG 2/4885RARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.